J
Jedd D. Wolchok
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 795
Citations - 154490
Jedd D. Wolchok is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Ipilimumab & Immune system. The author has an hindex of 140, co-authored 713 publications receiving 123336 citations. Previous affiliations of Jedd D. Wolchok include Ludwig Institute for Cancer Research & University of York.
Papers
More filters
Journal Article
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials
Jedd D. Wolchok,Jeffrey S. Weber,Omid Hamid,Céleste Lebbé,Michele Maio,Dirk Schadendorf,Veerle de Pril,Kevin N. Heller,Tai-Tsang Chen,Ramy Ibrahim,Axel Hoos,Steven J. O'Day +11 more
TL;DR: P pooled efficacy and safety data are presented according to HLA-A*0201 status and dose from pretreated patients randomized to 0.3, 3, or 10 mg/kg ipilimumab in four phase II trials to support the hypothesis that ipILimumab-treated patients with advanced melanoma have similar outcomes regardless of their HLA*0 201 status.
Journal ArticleDOI
18F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma.
Kimiteru Ito,Rebecca Teng,Heiko Schöder,John L. Humm,Ai Ni,Laure Michaud,Reiko Nakajima,Rikiya Yamashita,Jedd D. Wolchok,Jedd D. Wolchok,Wolfgang A. Weber +10 more
TL;DR: In patients with metastatic melanoma treated with ipilimumab, tumor response according to PERCIST was associated with OS and the data suggest that PMD should not be defined by the appearance of new lesions, but rather by an increase in the sum of SULpeak.
Journal ArticleDOI
A Single Heteroclitic Epitope Determines Cancer Immunity After Xenogeneic DNA Immunization Against a Tumor Differentiation Antigen
Jason S. Gold,Cristina R. Ferrone,José A. Guevara-Patiño,William G. Hawkins,Ruben Dyall,Manuel E. Engelhorn,Jedd D. Wolchok,Jedd D. Wolchok,Jonathan J. Lewis,Jonathan J. Lewis,Alan N. Houghton,Alan N. Houghton +11 more
TL;DR: In this model of xenogeneic DNA immunization, the presence of an hgp100 heteroclitic epitope with a higher affinity for MHC created by three amino acid substitutions at predicted minor anchor residues was necessary and sufficient to induce protective tumor immunity in H-2b mice with melanoma.
Journal ArticleDOI
Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors
TL;DR: It is shown that MDSCs are the critical cell population in IDO-expressing B16 tumors in mediating accelerated tumor outgrowth and resistance to immunotherapy, and inhibition of CSF-1R signaling can functionally block tumor-infiltrating M DSCs and enhance anti-tumor T cell responses.
Journal ArticleDOI
Non-conventional inhibitory CD4+Foxp3−PD-1hi T cells as a biomarker of immune checkpoint blockade activity
Roberta Zappasodi,Sadna Budhu,Matthew D. Hellmann,Matthew D. Hellmann,Michael A. Postow,Michael A. Postow,Yasin Senbabaoglu,Sasikanth Manne,Billel Gasmi,Cailian Liu,Hong Zhong,Yanyun Li,Alexander C. Huang,Alexander C. Huang,Daniel Hirschhorn-Cymerman,Katherine S. Panageas,E. John Wherry,E. John Wherry,Taha Merghoub,Jedd D. Wolchok +19 more
TL;DR: It is found that lack of effective 4PD1hi reduction after anti-PD-1 correlates with poor prognosis, and evidence that anti-CTLA-4 activity is improved in TFH deficient mice is provided.